Literature DB >> 20574403

Management of infections caused by vancomycin-resistant gram-positive bacteria.

Bindiya Bagga1, Jerry L Shenep.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20574403     DOI： 10.1097/INF.0b013e3181e78efc

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN： 0891-3668            Impact factor:   2.129


× No keyword cloud information.
  4 in total

Review 1.  Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens.

Authors:  Biswadeep Das; Chayna Sarkar; Debasmita Das; Amit Gupta; Arnav Kalra; Shubham Sahni
Journal:  Ther Adv Infect Dis       Date:  2017-03-08

2.  Feasibility, efficacy, and adverse effects of outpatient antibacterial prophylaxis in children with acute myeloid leukemia.

Authors:  Hiroto Inaba; Aditya H Gaur; Xueyuan Cao; Patricia M Flynn; Stanley B Pounds; Viswatej Avutu; Lindsay N Marszal; Scott C Howard; Ching-Hon Pui; Raul C Ribeiro; Randall T Hayden; Jeffrey E Rubnitz
Journal:  Cancer       Date:  2014-03-26       Impact factor: 6.860

3.  Telavancin: A novel lipoglycopeptide antibiotic.

Authors:  S E Damodaran; S Madhan
Journal:  J Pharmacol Pharmacother       Date:  2011-04

4.  Distribution of drug-resistant bacteria and rational use of clinical antimicrobial agents.

Authors:  Chenliang Zhou; Xiaobing Chen; Liwen Wu; Jing Qu
Journal:  Exp Ther Med       Date:  2016-04-08       Impact factor: 2.447
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.